Cargando…

EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression - a case report

Epstein-Barr virus (EBV)-associated B-cell post-transplantation lymphoproliferative disorder (PTLD) is a severe complication following stem cell transplantation. This is believed to occur as a result of iatrogenic immunosuppression leading to a relaxation of T-cell control of EBV infection and thus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krenauer, Alexander, Moll, Alexander, Pönisch, Wolfram, Schmitz, Nicole, Niedobitek, Gerald, Niederwieser, Dietger, Aigner, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853499/ https://www.ncbi.nlm.nih.gov/pubmed/20356360 http://dx.doi.org/10.1186/1746-1596-5-21

Ejemplares similares

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes
por: Mika, Thomas, et al.
Publicado: (2019)

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients
por: Jentzsch, Madlen, et al.
Publicado: (2017)

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia
por: Gratwohl, Alois, et al.
Publicado: (2019)

641. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorder in EBV Seropositive Adult Lung Transplant Recipients
por: Heldman, Madeleine R, et al.
Publicado: (2023)

The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge
por: Niederwieser, Dietger
Publicado: (2021)

Editorial: Allogeneic haematopoietic stem cell transplantation for children with acute lymphoblastic leukaemia in the era of immunotherapy
por: Peters, Christina, et al.
Publicado: (2022)

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation with the CD34(+)/CD38(-) population
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation
por: Brauer, Dominic, et al.
Publicado: (2021)

Post-transplant lymphoproliferative disorder: case report and review of susceptibility to EBV in the Scottish adult renal transplant pool
por: Selvarajah, Viknesh, et al.
Publicado: (2009)

Role of allogeneic haematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukaemia in the era of immunotherapy
por: Sun, Wei, et al.
Publicado: (2022)

Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2(+) T cells activities after hematopoietic transplantation for blood malignancies
por: Liu, Jiangying, et al.
Publicado: (2020)

Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder
por: Sen, Ayantika, et al.
Publicado: (2022)

P1560: EARLY DIAGNOSIS WITH EBV MONITOR AND PREEMPTIVE RITUXIMAB REDUCES POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER MORTALITY AND INCREASE OVERALL SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION
por: Liu, Jia-Hau, et al.
Publicado: (2023)

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
por: Fonseca-Hial, Ana Marcela Rojas, et al.
Publicado: (2016)

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Fatal Case of EBV-negative Posttransplant Lymphoproliferative Disorder With Hemophagocytic Lymphohistiocytosis in an Adult Kidney Transplant Recipient
por: Mazzola Poli de Figueiredo, Sergio, et al.
Publicado: (2022)

Single-center “Argentine” analysis of post-transplant lymphoproliferative disorders: incidence, histopathological characteristics and EBV status
por: Warley, Fernando, et al.
Publicado: (2023)

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
por: Jentzsch, Madlen, et al.
Publicado: (2022)

Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options
por: Clerico, Michele, et al.
Publicado: (2022)

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML
por: Jentzsch, Madlen, et al.
Publicado: (2020)

Ectopic jejunal pancreas with pancreatitis mistaken for a post-transplant lymphoproliferative disease in an immunosuppressed kidney transplant patient
por: Misheva, Bojana, et al.
Publicado: (2018)

Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice
por: Caduff, Nicole, et al.
Publicado: (2020)

Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience
por: Sakamoto, Hikaru, et al.
Publicado: (2019)

Characterization of EBV-related Lymphoproliferative Lesions Arising in Donor Lymphocytes of Transplanted Human Tumor Tissues in the NOG Mouse
por: Fujii, Etsuko, et al.
Publicado: (2014)

Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020)

Treatment Advances in EBV Related Lymphoproliferative Diseases
por: Lv, Kebing, et al.
Publicado: (2022)

The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world
por: Okamoto, Shinichiro, et al.
Publicado: (2022)

A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
por: Backhaus, Donata, et al.
Publicado: (2022)

Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice
por: Caduff, Nicole, et al.
Publicado: (2020)

Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond
por: Balduzzi, Adriana, et al.
Publicado: (2022)

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
por: Jentzsch, Madlen, et al.
Publicado: (2021)

Post-transplant lymphoproliferative disease
por: Dharnidharka, Vikas R., et al.
Publicado: (2009)

Mixed hepatoblastoma and teratoma of the liver in a 3-year-old child: a unique combination and clinical challenge
por: Moll, Alexander, et al.
Publicado: (2009)

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
por: Asleh, Rabea, et al.
Publicado: (2022)

EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood
por: Hong, Mineui, et al.
Publicado: (2013)

Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases
por: Kimura, Hiroshi, et al.
Publicado: (2019)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_v3d50dlc8sp88jc791na54kj6k